Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 2 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 2 21.
ORTHO TRI-CYCLEN 21 vs ORTHO-NOVUM 2-21
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing gonadotropin release. Additionally, induces changes in cervical mucus and endometrium.
Prevention of pregnancy
Prevention of pregnancy in women who elect to use oral contraceptivesTreatment of moderate acne vulgaris in females at least 15 years of age who have no known contraindications and have achieved menarche
One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.
One tablet orally once daily for 21 days followed by 7 days off. Each tablet contains norethindrone 2 mg and ethinyl estradiol 0.1 mg.
None Documented
None Documented
Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Norethindrone: terminal half-life 5-12 hours; ethinyl estradiol: terminal half-life 7-20 hours (enterohepatic recirculation may prolong effect). Steady-state achieved after 5-7 days.
Norgestimate: hydrolyzed to norelgestromin and norgestrel; metabolized by CYP3A4, CYP2C9, and CYP2C19. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation.
Ethinyl estradiol is metabolized primarily via CYP3A4, with contributions from CYP2C9 and CYP2C19. Norethindrone is metabolized via CYP3A4 and reduction pathways.
Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Renal (approx. 60% as metabolites), fecal (approx. 40% as metabolites). Norethindrone and ethinyl estradiol are extensively metabolized; less than 5% excreted unchanged in urine.
Norgestimate: ~99% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin; norethindrone (active metabolite) binds with similar high affinity.
Norethindrone: ~60% bound to albumin, ~1.5% to SHBG; ethinyl estradiol: ~97% bound to albumin (not to SHBG).
Norgestimate: Vd ~6-8 L/kg; ethinyl estradiol: Vd ~3-5 L/kg. Large Vd indicates extensive tissue distribution including breast, uterine, and hepatic tissues; clinical relevance: potential for drug interactions (e.g., enzyme inducers).
Vd for norethindrone: ~3.1±0.5 L/kg; for ethinyl estradiol: ~3.5–4.5 L/kg. Indicates extensive tissue distribution.
Oral: Norgestimate ~75% (first-pass metabolism limits bioavailability); ethinyl estradiol ~40-60% (substantial first-pass effect).
Oral: norethindrone ~64% (first-pass metabolism reduces it); ethinyl estradiol ~38-48% (high first-pass metabolism).
No specific dose adjustment is provided in manufacturer labeling; use with caution in patients with renal impairment. GFR-based adjustments are not established.
No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 mL/min) or dialysis, use is not recommended due to potential fluid retention and hypertension.
Contraindicated in patients with hepatic disease or hepatocellular carcinoma. Child-Pugh class B or C: contraindicated. Child-Pugh class A: use with caution, no specific dose adjustment defined.
Contraindicated in acute or chronic hepatocellular disease with abnormal liver function, including Child-Pugh class B or C. Adjustment not applicable in mild hepatic impairment (Child-Pugh class A) but use caution and monitor.
Safety and efficacy established in postmenarchal females; dosing is same as adult: one tablet daily for 21 days. Weight-based dosing not applicable.
Not indicated for use before menarche. After menarche, dosing is same as adult (one tablet daily for 21 days, then 7 days off). Weight-based guidelines are not established.
Not indicated for use in postmenopausal women. No specific considerations available.
Not indicated for postmenopausal women. No specific geriatric dosing adjustments have been studied.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (≥15 cigarettes/day). Women who use oral contraceptives should be strongly advised not to smoke.
["Thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, stroke, myocardial infarction)","Hepatic disease (including hepatic adenoma or carcinoma)","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism disturbances","Headache (including migraine with focal symptoms)","Uterine bleeding irregularities"]
["Thrombotic events (venous and arterial)","Cardiovascular risks in smokers over 35","Hepatic neoplasia","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism effects","Ocular lesions (retinal thrombosis)","Reduced efficacy with hepatic enzyme inducers"]
["Known or suspected pregnancy","Current or history of thromboembolic disorders (e.g., DVT, PE)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal genital bleeding","Hepatic adenoma or carcinoma, or active liver disease","Hypersensitivity to any component","Smoking in women over 35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with aura if >35 years","Major surgery with prolonged immobilization"]
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease","Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer or estrogen-dependent neoplasia","Hepatic adenoma or carcinoma (current or history)","Jaundice or liver disease (acute or chronic)","Hypersensitivity to any component","Smoking in women over 35 (<15 cigarettes/day is relative; >15 is absolute)"]
Data Pending Review
Data Pending Review
No specific food restrictions; however, grapefruit juice may increase estrogen levels (minor interaction). Avoid St. John's wort, which can reduce contraceptive efficacy.
No specific food restrictions; grapefruit juice may alter estrogen metabolism but clinical significance is unclear. Maintain consistent diet to avoid GI upset. Avoid excessive alcohol intake.
First trimester: Risk of congenital anomalies (limb defects, neural tube defects) based on case reports; overall risk low. Second/third trimester: Possible increased risk of intrauterine growth restriction and preterm birth. Postnatal: Potential for jaundice and transient hormonal effects in neonates.
Category X: Contraindicated in pregnancy. First trimester: Increased risk of cardiovascular and limb reduction defects. Second and third trimesters: Associated with feminization of male fetuses and potential for other teratogenic effects.
Contraindicated in breastfeeding due to estrogens reducing milk production and quality. Limited data; M/P ratio not established. Alternative methods preferred.
Contraindicated during breastfeeding due to potential for reduced milk production and excretion of estrogen/progestin into breast milk. M/P ratio: Not established.
No dose adjustments needed as drug is contraindicated during pregnancy. Discontinue immediately upon confirmed pregnancy; pharmacokinetic changes not applicable.
No dosing adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic metabolism, volume of distribution) are not relevant due to contraindication.
Category C
Category C
ORTHO TRI-CYCLEN 21 contains norgestimate and ethinyl estradiol; it is a triphasic oral contraceptive with varying hormone doses across 21 active pills. Its progestin component has low androgenicity, making it suitable for patients with acne or hirsutism. Monitor for thromboembolic risk, especially in smokers over 35. Missed pill management: if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception and consider emergency contraception.
Monitor for thromboembolic events, especially in smokers over 35. Counsel about missed dose protocol: take as soon as remembered, use backup contraception if >12 hours late. Caution with hepatic enzyme inducers (e.g., rifampin, anticonvulsants) reducing efficacy. Check BP at baseline and periodically. Consider VTE risk with obesity or immobilization. Not for use in pregnancy or breastfeeding.
Take one pill daily at the same time for 21 days, then 7 placebo pills.Use backup contraception (e.g., condoms) for the first 7 days of initial use.Common side effects: nausea, breast tenderness, breakthrough bleeding; these often improve after 2-3 cycles.Report signs of blood clots: leg pain/swelling, chest pain, sudden shortness of breath, severe headache.Smoking increases blood clot risk; do not smoke while using this medication.If severe vomiting or diarrhea occurs within 4 hours after taking a pill, consider it missed and follow missed pill instructions.
Take one tablet daily at the same time, even if not sexually active.If you miss a dose, take it as soon as you remember; if more than 12 hours late, use backup contraception for 7 days.Smoking increases risk of serious cardiovascular side effects, especially in women over 35.Notify your doctor if you experience leg pain/swelling, chest pain, shortness of breath, severe headache, or vision changes.This medication does not protect against HIV or other STDs.Inform all healthcare providers that you are taking this drug.